Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer NSCLC and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics Inc.

In a report released today, from Mizuho Securities maintained a Buy rating on Iovance Biotherapeutics, with a price target of $10.00. In addition t...

Mizuho Securities Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics (($IOVA)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call of Iovance B...

Iovance Biotherapeutics Reports Positive Earnings Amid Growth

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics, with a price target of $9.00....

Iovance Biotherapeutics (IOVA) Gets a Buy from H.C. Wainwright

Barclays analyst Peter Lawson maintained a Buy rating on Iovance Biotherapeutics today and set a price target of $4.00. The company’s shares closed...

Barclays Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics (($IOVA)) announced an update on their ongoing clinical study. Study Overview: Iovance Biotherapeutics is conducting a Phas...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IOVA	$2.23	+2.33%	6.19M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IOVA	$2.23	+2.3%	6.19M
3
4
5
6

IOVA

IOVA

No Data Available

Get Iovance Biotherapeutics Inc. Data in Excel

Get Iovance Biotherapeutics Inc. Data in Excel